Immunotherapy is a promising treatment option for cancer patients. However, the response rate remains low at approximately 20%. Therefore it is crucial to consider predictive biomarkers in patients’ treatment plans to identify those who will respond to immunotherapy.
TODSYHEALTH TME is an RNA-based immune profiling assay that enables the characterization of tumor-immune microenvironment beyond traditional “immune-filtrated” or “non-immune-filtrated” classification, providing insights to facilitate immune-oncology drug development.
Profiles > 90 cancer genes to evaluate immunotherapy
Proprietary chip-based multiplex qPCR platform
Fast turnaround time
Accommodates highly degraded specimens with low inputs
MHC I Pathway
Memory CD8 T Cell
Tumor Secretory Cytokines
Active CD4 T Cell
Active CD8 T Cell
Regulatory T Cell
Immune Escape Mechanism
Memory CD4 T Cell
TODSYSHEALTH® sequences genes involved in immune response and antigen processing and presenting machinery. The mutation statuses of these genes will be considered when recommending immunotherapy. TODSYSHEALTH® covers TMB, MSI and immune-related genes to evaluate the use of immunotherapy.
Tumor Mutational Burden (TMB)
Microsatellite Instability (MSI)
© 2019 Todsyshealth. All rights reserved.